Keywords: Servier, Perindopril, Antitrust, European Commission, Pay-for-delay deals, Generic entry, Teva, Mylan
EU Commission focus now on Servier and others re-perindopril antitrust issues
Article | 31 July 2012
The European Commission has informed French independent pharmaceutical company Servier and several of its generic competitors of its objections against ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
